Replicor to present pre-clinical and clinical data on REP 2139-Ca based combination therapy in chronic HBV / HDV co-infection at HEPDART 2015
NEW YORK, December 1, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and clinical data on REP 2139-Ca based combination therapies in HBV monoinfection and HBV / HDV co-infection at the 2015 HEPDART meeting to be held from December 6-10, 2015 in Wailea, Hawaii. These presentations will be made during the poster session on December 8th.
Poster #114 will present the preclinical assessment of interferon-free combination therapy with REP 2139-Ca and tenofovir disoproxil fumarate (TDF) and entecavir (ETV) to establish control of HBV infection in the liver using the duck model of HBV infection. In this study, combining REP 2139-Ca with TDF and ETV improved the speed of on-treatment antiviral response and lead to the control of infection in the liver of most ducks including multi-log reductions in liver DHBV DNA and cccDNA and disappearance of duck HBsAg from the liver.
Poster #60 will present the interim efficacy data from the ongoing REP 301 trial (NCT02233075) assessing the safety and efficacy of REP 2139-Ca used in combination with pegylated interferon alpha 2a in Caucasian patients with HBV / HDV co-infection. HBsAg reductions during combined therapy with REP 2139-Ca and pegylated interferon alpha-2a continued to decline, becoming > 6 logs in 4 patients (0.01 IU / ml), > 5 logs in 2 patients, > 3 logs in 2 patients and 0.5-2.78 logs in the remaining 4 patients. HDV RNA is now currently undetectable in ten patients (~5-8 log reduction from baseline). The addition of pegylated interferon alpha-2a to therapy was associated with dramatic increases in free anti-HBs (to levels as high as 20,665 mIU / ml) and liver flares, but only in those patients who achieved serum HBsAg 4 log reduction from baseline) at the start of immunotherapy.
These pre-clinical and clinical studies continue to advance Replicor’s understanding of how different REP 2139-Ca based combination therapies will benefit patients with HBV infection or HBV / HDV co-infection.
For the HEPDART 2015 meeting and preliminary program:
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.